Portrazza Market Report 2026

Portrazza Market Overview

• The Portrazza market growth in the historic period has been driven by increasing prevalence of non-small cell lung cancer, advancements in monoclonal antibody development • Market expansion is supported by increasing demand for precision oncology therapies, rising investments in biologic cancer drugs • Growth Driver: Increasing Incidence Of Lung Cancer Driving Growth In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Portrazza Market?

Portrazza is a biologic drug that contains necitumumab, a monoclonal antibody used for the treatment of non-small cell lung cancer (NSCLC). It works by targeting and blocking the epidermal growth factor receptor (EGFR), which contributes to the growth and survival of cancer cells. The main indications in the portrazza market include metastatic squamous non-small cell lung cancer (NSCLC) and locally advanced squamous NSCLC. Metastatic squamous NSCLC refers to the stage where the cancer has spread to other parts of the body, with treatments aimed at controlling its progression and enhancing the patient’s quality of life. The drug is distributed through multiple channels, including direct sales, pharmaceutical wholesalers, and online pharmacies. Its end users encompass hospitals, oncology clinics, and home healthcare providers.

What Is The Portrazza Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for precision oncology therapies, rising investments in biologic cancer drugs, expansion of egfr-targeted treatment pipelines, growing adoption of combination regimens, increasing focus on personalized lung cancer management. Major trends in the forecast period include increasing use of egfr-targeted monoclonal antibodies, rising adoption in lung cancer treatment protocols, growing focus on targeted oncology biologics, expansion of combination therapy approaches, enhanced emphasis on personalized cancer care.

Global Portrazza Market Segmentation

1) By Indication: Metastatic Squamous Non-Small Cell Lung Cancer, Locally Advanced Squamous Non-Small Cell Lung Cancer 2) By Distribution Channel: Direct Sales, Pharmaceutical Wholesalers, Online Pharmacies 3) By End User: Hospitals, Oncology Clinics, Home Healthcare Providers

What Are The Drivers Of The Portrazza Market?

The increasing incidence of lung cancer is expected to propel the growth of the portrazza market going forward. Lung cancer refers to a type of cancer that begins in the lungs, typically in the cells lining the air passages, and can spread to other parts of the body. The increasing incidence of lung cancer is attributed to factors such as smoking, exposure to environmental pollutants, genetic predisposition, and occupational hazards like asbestos. Portrazza (necitumumab) treats lung cancer by targeting and inhibiting the epidermal growth factor receptor (EGFR), which plays a key role in the growth and spread of cancer cells, thereby slowing the progression of non-small cell lung cancer (NSCLC) in combination with chemotherapy. For instance, according to the American Cancer Society Facts and Figures, a US-based professional organization, the estimated number of new lung and bronchus cancer cases in the US increased from 236,740 in 2022 to 238,340 in 2023. Therefore, the increasing incidence of lung cancer is driving the growth of the portrazza industry. The rising healthcare expenditure is expected to fuel the growth of the portrazza market going forward. Healthcare expenditure refers to the total amount of money spent on healthcare services and products, including hospital care, physician services, prescription drugs, and other medical goods and services. Rising healthcare expenditure is attributed to factors such as an aging population, more chronic diseases, medical advancements, and increased healthcare demand, all leading to higher costs. Healthcare expenditure on Portrazza supports its accessibility for patients requiring treatment for advanced squamous non-small cell lung cancer. It also enables ongoing research, improved treatment protocols, and better patient outcomes through targeted therapy. For instance, in April 2025, according to the Office for National Statistics, a UK-based government agency, UK healthcare expenditure was approximately US$414 billion (£317 billion) in 2024. Further, between 2023 and 2024, total healthcare expenditure grew by 6.5% in nominal terms. Therefore, the rising healthcare expenditure is driving the growth of the portrazza industry. The shift toward personalized medicine is expected to boost the portrazza market going forward. Personalized medicine refers to healthcare that tailors medical decisions, treatments, and practices to the individual patient based on their genetic profile and other personal information. The shift toward personalized medicine is attributed to advancements in genomics, biotechnology, and data analytics, enabling tailored treatments based on individual genetic profiles. Portrazza (necitumumab) is beneficial for personalized medicine, as it targets the epidermal growth factor receptor (EGFR) to specifically treat non-small cell lung cancer (NSCLC) with EGFR expression, offering a more tailored treatment approach based on the patient's unique biomarker profile. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based healthcare organization, the Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, a significant increase from six approvals in 2022. Therefore, the shift toward personalized medicine is driving the growth of the portrazza industry.

Key Players In The Global Portrazza Market

Major companies operating in the portrazza market are Eli Lilly and Company

Regional Insights

North America was the largest region in the portrazza market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Portrazza Market?

The portrazza market consists of sales of portrazza (necitumumab) injections, chemotherapy drugs, and supportive care drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Portrazza Market Report 2026?

The portrazza market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the portrazza industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.